Open an account

Ernexa Therapeutics

ERNA · NASDAQ

$2.24+$0.26 (+13.13%)TodayMarket closed ·
Prev close $1.98

About ERNA

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 5 full-time employees. The firm is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The firm seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The firm is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.

Employees
5
Headquarters
Cambridge, Massachusetts
Listed
Aug 29, 1991
Sector
Health Care
Industry
Biotechnology
Website
ernexatx.com

ERNA key statistics

Market cap
3.66M
Price-earnings ratio
0.00
Dividend yield
0.62%
Average volume
69.23K
Volume
48.19K
Open price
$1.90
High today
$2.26
Low today
$1.89
52 Week high
$71.50
52 Week low
$1.84

Ernexa Therapeutics (ERNA) at a glance

As of Oct 20, 2026, Ernexa Therapeutics (ERNA) shares are priced at $2.24, giving the company a market cap of 3.66M, a price-to-earnings ratio of 0.00 and a dividend yield of 0.62%.

Today the stock has traded between $1.89 and $2.26. The current price is 18.5% above the day's low and 0.9% below its high.

Volume so far is 48.19K shares, below the average of 69.23K shares a day.

Over the past year Ernexa Therapeutics has ranged from $1.84 to $71.50, and now sits 1% of the way up that range.

Ernexa Therapeutics met or beat analyst EPS estimates in 1 of the last 8 quarters. In Q2 FY26 it reported -$3.40 per share against an estimate of -$3.37.

The average analyst price target is $30.60, 1266.1% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $30.60
Low
$30.30
Now
$2.24
High
$31.50

ERNA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 54.8% on average.

  1. Q4 FY18: reported $1,650.00 per share against an estimate of $2,295.00
  2. Q3 FY21: reported -$825.00 per share against an estimate of -$612.00
  3. Q4 FY21: reported -$1,200.00 per share against an estimate of -$956.25
  4. Q1 FY22: reported -$1,275.00 per share against an estimate of -$1,071.00
  5. Q2 FY22: reported -$450.00 per share against an estimate of -$994.50
  6. Q3 FY22: reported -$933.75 per share against an estimate of -$841.50
  7. Q3 FY23: reported -$1.03 per share against an estimate of $0.00
  8. Q2 FY26: reported -$3.40 per share against an estimate of -$3.37

ERNA news

  • Vandana Singh

    Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell Therapy

  • Press releaseGlobe Newswire

    Three Biotechs Deliver Catalysts to Watch

  • Avi Kapoor

    Dow Gains Over 150 Points; Morgan Stanley Profit Tops Views

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • Evette Mitkov

    Ernexa Stock Is Jumping Today: What's Going On?

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Avi Kapoor

    Nasdaq Dips Over 1%; US Inflation Surges To 3.8% In April

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

Similar companies

Companies in the same industry as Ernexa Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.